

CMBI Credit Commentary

Hopson: Businesses have been largely as usual

HPDLFs offer good value; maintain buy

Offered at 82.1 and 70.0, HPDLF'23 and '24 are trading at YTM of 73.7% and 65.7%, respectively. We continue to see Hopson a survivor for the sector and consider the current valuations of HPDLFs offer attractive risk-return profile. We maintain buy on HPDLFs in view of its solid operating performance in a very challenging environment, manageable debt maturities and adequate liquidity profile, supported by its offshore financial investments and high quality investment properties (IPs). As repeatedly discussed before, we are impressed with Hopson's proven track records in full repayments in tough funding environment. Recalled that it repaid, rather than refinanced, CBs of RMB1.8bn in Feb'10, straight bonds of USD350mn in Sep'12, USD300mn in Jan'18, HKD720mn in Jul'22 and CBs of USD250mn in Jan'23 in a challenging market environment.

	O/S (USD mn)	Maturity	Coupon	Offer price	YTM (%)
HPDLF 6.8 12/28/23	237.5	12/28/2023	6.80%	82.1	73.7%
HPDLF 7 05/18/24	300	5/18/2024	7.00%	70.0	65.7%

Source: Bloomberg.

“Surprisingly” solid 1H23 results

HKD mn (except otherwise stated)	1H22	1H23	% change
Contract sales (RMB mn)	16,860.0	16,062.0	-4.7%
Revenue	13,170.4	15,079.9	14.5%
Property sales	9,282.3	11,320.2	22.0%
Recurring income	5,707.7	3,682.3	-35.5%
Investment income	-1,819.6	77.3	-104.3%
Gross profit	3,064.4	5,377.2	75.5%
Profit before tax	8,683.1	6,187.8	-28.7%
Attributable net core profit	559.0	1,581.0	182.8%
Recognized GFA (mn sqm)	473.0	543.3	14.8%
Recognized ASP/sqm (RMB)	14,511.0	18,479.0	27.3%
Gross margin	23.3%	35.7%	
Net core profit margin	4.2%	10.5%	

Source: Company fillings.

Hopson reported a solid set of 1H23 results. Its attributable net core profit increased 182.8% to HKD1.6bn while gross margin and net core profit rebounded to 35.7% and 11.2% in 1H23. The strong results reflected higher GFA delivered, higher recognized ASP and reversal of investment losses in 1H22. The profit margin of Hopson has always been at the high end of the sector, reflecting its low cost and high quality land bank secured gradually over the years. As at Jun'23, 74% of its GFA was in T1 cities. Taking cues from the higher ASP of contract sales YTD, we expect Hopson's margin to maintain at the high end of the sector.

Glenn Ko, CFA 高志和
 (852) 3657 6235
 glennko@cmbi.com.hk

Cyrena Ng, CPA 吳衛瑩
 (852) 3900 0801
 cyrenang@cmbi.com.hk

Jerry Wang 王世超
 (852) 3761 8919
 jerrywang@cmbi.com.hk

In 7M23, its contracted ASP was RMB34,622/sqm compared with recognized ASP of RMB18,479/sqm. As per our previous discussions with Hopson, it expects its gross margin for property developments to be 25-30% over the coming 1-2 years.

In 7M23, Hopson achieved total contract sales of RMB17.1bn (including decoration contract sales), declined 9% yoy. The decline is much more moderate compared with an average decline of 26% for the 35 developers under our radar. The more resilience operating performance was attributable to Hopson's focus on T1 cities. In 1H23, 86% of its contract sales were from T1 cities. Hopson is confident to achieve FY23 sales target of cRMB37bn (HKD40bn). Based on its saleable resources of RMB80bn (including projects in Beijing, Guangzhou and Shanghai) in 2H23, Hopson will complete the full year target as long as the sell-through rate in 2H23 hit 30%. The sell-through rate for previous year was 50-60%.

Net debt reduction with manageable debt maturity profile

HKD mn	Jun'22	Dec'22	Jun'23
Cash	28,262.0	18,394.2	18,996.7
<i>Cash in escrow</i>			
ST debts	31,835.7	26,002.5	30,063.6
LT debts	73,856.0	72,194.1	62,842.6
Total debts	105,691.7	98,196.5	92,906.2
Net debts	77,429.7	79,802.3	73,909.5
Net gearing	68.3%	81.1%	74.5%
Cash/ST debts	0.9x	0.7x	0.6x
Adj. liab/assets	60.0%	61.2%	59.9%

Source: Company fillings.

Hopson maintained a largely stable credit profile. In 1H23, its net debts reduced 7.4% to HKD73.9bn (cRMB69bn) in 1H23. We expect further net debt reduction in view of the company's guidance of positive free cash of cRMB9bn in 2H23. Subsequent to the repayment in Jul-Aug'23, its ST debts due before Jun'24 was RMB23.1bn equivalent. Hopson expects to roll over RMB12.6bn of these and extend their maturities by 1-2 years on the back of supportive onshore refinancing policies. The remaining ST debts to be repaid will be cRMB10.5bn, including USD bonds of USD237.5mn due Dec'23 and USD300mn due May'24 and offshore loans. As per Hopson, about 20-30% of its cash on hand is restricted in the escrow account on a rolling basis. That implied its unrestricted cash to be cRMB12-14bn (USD1.6-1.9bn) available for uses such as offshore debt repayments as at Jun'23. We believe that the repayment requirements of RMB10.5bn should be well covered by its unrestricted cash on hand and positive free cash flow over in 2H23 and 1H24. Furthermore, it had IPs of cRMB80bn, and loans against these IPs were cRMB26bn, equivalent to LTV of c33%. Hopson mentioned that it did not have an immediate plan to obtain additional secured financing through its IPs. That said, we believe that its high quality IP portfolio will offer an alternative source of liquidity if needed. We estimate the headroom of additional secured financing against its IPs to be RMB22-30bn if Hopson raises the LTV to the industry norm of 60-70%.

Offshore investment portfolio offers will be another source of liquidity

The book value of its financial assets was HKD5.7bn (cUSD730mn), out of these, HKD1.2bn (cUSD150mn) were booked under current financial assets which were mainly HK-listed equities. The non-current financial assets were mainly pre-IPO and PE investments. We believe that the declining financial assets partly reflected Hopson's divestments given the market volatility, and partly reflected the lower market value of its investments. Hopson also owns 9.1% stakes in Ping An Healthcare of cUSD250mn booked under investments in JVs. Based on the public disclosures (for listed investments of >5% of outstanding shares), the market value of Hopson's listed investments in

HKEX is cHKD3.3bn (cUSD420mn), including the stakes in Ping An Healthcare. We estimate that the value of its financial investments and listed investments in Ping An Healthcare to be cHKD7.8bn (cUSD1bn or RMB7.3bn). Even after deducting for margin loans of HKD882.9bn, these offshore investments represent a significant offshore liquidity source.

CMB International Global Markets Limited

Fixed Income Department

Tel: 852 3761 8867/ 852 3657 6291

fis@cmbi.com.hk

CMB International Global Markets Limited("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclosure:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US, institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.